ArticlePloS one2017
Decellularized extracellular matrices produced from immortal cell lines derived from different parts of the placenta support primary mesenchymal stem cell expansion.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Usefulness of Mesenchymal Cell Lines for Bone and Cartilage Regeneration Research.International journal of molecular sciences · 2019Pooled it
- Immortalized human hair follicle-derived mesenchymal-like stromal cells for the long-term production of scalable Immunomodulatory and regenerative secretome.Stem cell research & therapy · 2025Article
- Therapeutic potential of extracellular vesicles for treating human pregnancy disorders.Extracellular vesicles and circulating nucleic acids · 2025Review
- Engineering cell-derived extracellular matrix for peripheral nerve regeneration.Materials today. Bio · 2024Review
- MSCs-Derived Decellularised Matrix: Cellular Responses and Regenerative Dentistry.International dental journal · 2024Review
- Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).Stem cell research & therapy · 2023Article
- Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.Stem cell research & therapy · 2022Review
- Highlights on Advancing Frontiers in Tissue Engineering.Tissue engineering. Part B, Reviews · 2022Review
- Improvement of Mesenchymal Stromal Cell Proliferation and DifferentiationFrontiers in medical technology · 2022Article
- Effect of Decellularized Extracellular Matrix Bioscaffolds Derived from Fibroblasts on Skin Wound Healing and Remodeling.Frontiers in bioengineering and biotechnology · 2022Article
- Stem cells immortalized by hTERT perform differently from those immortalized by SV40LT in proliferation, differentiation, and reconstruction of matrix microenvironment.Acta biomaterialia · 2021Article
- The Chondrogenic Potential of First-Trimester and Term Placental Mesenchymal Stem/Stromal Cells.Cartilage · 2021Article
- Article
- Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.Cellular and molecular life sciences : CMLS · 2020Review
- A simple segmentation and quantification method for numerical quantitative analysis of cells and tissues.Technology and health care : official journal of the European Society for Engineering and Medicine · 2020Article
- Extracellular matrix from decellularized mesenchymal stem cells improves cardiac gene expressions and oxidative resistance in cardiac C-kit cells.Regenerative therapy · 2019Article
- Recent Trends in Decellularized Extracellular Matrix Bioinks for 3D Printing: An Updated Review.International journal of molecular sciences · 2019Review
- Multiplicity of Mesenchymal Stromal Cells: Finding the Right Route to Therapy.Frontiers in immunology · 2019Review
- Extracellular matrix-derived biomaterials in engineering cell function.Biotechnology advancesReview
- Decellularized extracellular matrix for organoid and engineered organ culture.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem/stromal cells (MSCs) exhibit undesired phenotypic changes during ex vivo expansion, limiting production of the large quantities of high quality primary MSCs needed for both basic research and cell therapies. Primary MSCs retain many desired MSC properties including proliferative capacity and differentiation potential when expanded on decellularized extracellular matrix (dECM) prepared from primary MSCs. However, the need to use low passage number primary MSCs (passage 3 or lower) to produce the dECM drastically limits the utility and impact of this technology. Here, we report that primary MSCs expanded on dECM prepared from high passage number (passage 25) human telomerase reverse transcriptase (hTERT) transduced immortal MSC cell lines also exhibit increased proliferation and osteogenic differentiation. Two hTERT-transduced placenta-derived MSC cell lines, CMSC29 and DMSC23 [derived from placental chorionic villi (CMSCs) and decidua basalis (DMSCs), respectively], were used to prepare dECM-coated substrates. These dECM substrates showed structural and biochemical differences. Primary DMSCs cultured on dECM-DMSC23 showed a three-fold increase in cell number after 14 days expansion in culture and increased osteogenic differentiation compared with controls. Primary CMSCs cultured on the dECM-DMSC23 exhibited a two-fold increase in cell number and increased osteogenic differentiation. We conclude that immortal MSC cell lines derived from different parts of the placenta produce dECM with varying abilities for supporting increased primary MSC expansion while maintaining important primary MSC properties. Additionally, this is the first demonstration of using high passage number cells to produce dECM that can promote primary MSC expansion, and this advancement greatly increases the feasibility and applicability of dECM-based technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.